TWI355272B - Food and pharmaceutical composition with strains o - Google Patents

Description

1355272 VI. Description of the Invention: [Technical Field] The present invention relates to a food composition and a pharmaceutical composition, and more particularly to a food composition and a pharmaceutical composition comprising an antiallergic lactic acid bacteria strain. [Prior Art] Generally, the products containing lactic acid bacteria (LAB) only have the health effect of adjusting the intestinal tract. Although there are tens of thousands of lactic acid bacteria strains in nature, only a few lactic acid strains have the characteristics of being allergic. The ability of a few of these bacterial strains to have acid and bile salt tolerance, ability to adsorb mucosal epithelial cells, and ability to survive after passage through the gastrointestinal tract is an important basis for screening for strains that promote health effects. Since then, only a few strains of lactic acid bacteria have been identified that have been shown to have anti-allergic health effects, and the function of lactic acid bacteria for health is the specificity of the strain rather than the species. The strains of the human health are known as the functional probiotics (Guidelines f〇r evaluation of probiotics in food; Report of joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food; London Ontario, Canada April 30 and May 1, 2002 : 1-7) ° There are many reports on lactic acid bacteria related to allergic reactions at home and abroad. In an animal test study on the ability of lactic acid bacteria to reduce allergies, the animal test of the heat-killing lactic acid bacteria 〆 L L-137 can induce the production of IL-12 and IFN- in macrophages and spleen cells of DBA/2 mice. γ, and can suppress IgE which has casein specificity, and increase igGi antibody specific for casein (Mur〇saki, 1998). In order to increase the secretion of spleen cells and IL-12 around the OVA-TCR-Tg rat food I. msez Shirota, the secretion of IL-4 and IL-5 was reduced (Shida et al., 20〇2). OVA sensitization BALB/c

Rats fed lactic acid bacteria fermented milk for 27 days reduced IgE with 〇VA specificity in serum (Ishida et al_, 2003). C3H/Hej mice are sensitized with 0VA and cholera toxin (ch〇lera toxin), fed and 6 ng/wm BGN4, I· 911, which can reduce 特异性VA 3 1355272 specific IgE, IgA and total IgE, IgGl in serum. (Kim et al., 2005), these documents confirm that in the animal test of allergic patterns, the lactic acid bacteria can reduce the content of 10% in the serum, thereby improving the allergy. Lactic acid bacteria in clinical trials, patients with allergic diseases can indeed improve allergic reactions' combined with dry lactic acid bacteria I. r/wmwwwi and rewim· six weeks, have an advantage for allergic diseases, questionnaires to assess parents to probiotics for one to ten Three-year-old children with atopic dermatitis found 56% of children with atopic dermatitis improved (Rosenfeidt et ai., 2〇〇3) 〇 Ishida (2005) scholars for forty-nine patients with allergic rhinitis, drinking z Blood soil L-92 'also found that allergic symptoms have been improved ❶ taking • Eight weeks 'fifty-three children with atopic dermatitis symptoms can increase IFN-r production in pBMC cells and improve allergic conditions (prescott et al., 2005). Falster_H〇lst (2〇〇6) and other scholars have pointed out that the test of 54 patients with atopic dermatitis, after taking L. strain GG and placebo, can effectively improve allergy symptoms. Studies have shown that the cell wall components of lactic acid bacteria have immunomodulatory capabilities, including - Peptid〇glycans (PG), LiP〇teich〇ic adds (LTA), and Ph〇Sph_y read harme. For example, I. Phosphopolysaccharide in the cell wall stimulates mouse leukocytes to produce IFN-7' Teichoic acid and Muramyl dipeptide. Increased stimulation of PBMC produces positive 1<[- 7 (Cross et al_, 2001); eg _ KW3u〇 cell wall component LTA can affect The signal transmission pathway has strong immunomodulatory ability (Fujiwara et al., 2004). 'Probiotic strains have good efficacy for the human body' and there are many possible mechanisms to explain why probiotics have a good effect on the human body. Most of them focus on improving the secret function of the intestinal mucosa to directly affect the immune system of the human body, for example It inhibits the secretion of proinflammatory cytokines, affects the activity of regulatory tau cells, and adjusts the balance between Th1/Th2. It is very important to improve the regulation of gastrointestinal symbiosis in infants and young children. Many infants with allergies lack probiotic _ plexus, and there are more gas-producing Clostridium and less double in intestinal flora. Laparotherapy rods. Therefore, probiotic g-cluster exists in the intestine, which is very important for the construction of human immunity and the ability to have a strong immune function. However, 4 1355272 » * and 'the mechanism of affecting the human body by probiotics has not yet been determined. In view of this, in the future development, more in vitro and in vivo tests are needed to explain, so good for the human body. The mechanism and the best conditions for research in humans (Michael et al., 2008). SUMMARY OF THE INVENTION The present invention broadly includes any of the following biological cultures: Lactobacillus velfcn_) GL-104 strain, Food Industry Development Institute, accession number BCRC 910404 and Lactobacillus strain, Food Industry Development Institute A food composition or pharmaceutical composition consisting of the accession number BCRC 910441, and a physiologically acceptable excipient or # diluent. In another specific embodiment, the biological culture of the same or a mutant of any one of the following strains which is physiologically acceptable to enhance anti-allergic ability: Lactobacillus calvaryrum m^r〇GL-104 strain' food industry development The Institute registered number BCRC 910404 and Lactobacillus (/^£加^//财喜伽7) D5-33 strain, Food Industry - Industry Development Institute registration number BCRC 910441. In a further embodiment, the invention broadly comprises inhibiting the immune response by regulating the Th1 type immune response by promoting intercellular melanin (iL-η) or interferon (IV), and improving the Th2 by immunoglobulin IgE' An allergic phenomenon of excess immune response, which is administered to a mammal to any of the foregoing biological cultures that achieve a dose that stimulates a Th1 type immune effect. The invention may also be broadly construed as including a part or a combination of elements and features in the description of the application, and any or all combinations of any one or more of those parts, constituent elements and features. And, if the equivalents are described in the related art, the known equivalents will be incorporated herein as separate matters. [Embodiment] 5 1355272 The present invention broadly encompasses any of the following biological cultures: Lactobacillus reesei W) GL-104 strain, Food Industry Development Institute registration number • BCRC 910404 and Lactobacillus reMierz) A TE-33 strain, Food Industry and Industry Development Institute, accession number BCRC 910441, and a food composition or pharmaceutical composition comprising a physiologically acceptable excipient or diluent. Many literatures have pointed out that increasing the secretion of type 1 T cell cytokines including interleukin (IL-12) and interferon y (IFN-gamma) can effectively improve allergy symptoms; further studies have pointed out specific lactic acid strains and trees. On the stellate cell, the sputum receptor (T〇1l_like recto) binds to 'activated intracellular translational proteins and releases a large amount of cytokines. · It belongs to a part of innate immunity, so some specific lactic acid bacteria strains Cell wall polysaccharides such as peptidoglycan, polysaccharide, etc., through the innate immune system, can indeed activate the development of T cells in the body. The strain of the present invention is cold; the bundle dried culture has been deposited in the Taiwan Food Industry Development - Research Institute, and the address is No. 331, Food Road, Hsinchu City, Republic of China. The details of the registration are shown in Table _: Table 1 The name of the strain is Lactobacillus GL-104 BCRC910404. The Lactobacillus TE-33 BCRC910441, January 29, 2009, August 28, 2009 Two strains of lactic acid bacteria have been found to have anti-allergic capabilities, including atopic dermatitis, urticaria, allergic rhinitis, food allergies and asthma = a function of slowing and treating. Example 1: Morphology and general properties of anti-allergic lactic acid bacteria. The taxonomic characteristics of the strains were determined based on the 16S rDNA sequence analysis and the results of the API bacterial identification system analysis. It was found that Fenghua strain No. Gl-104 was a lactic acid rod Z; 6 1355272 morphological and general properties • & hua strain No. ΊΈ-33 is Lactobacillus. The characteristics of this bacterium are detailed in Table 2:

• When cultured in MRS medium, the g body is short rod-shaped and the two ends are solid, usually appearing alone, in pairs or in short chains.

2· f-L. staining-positive bacilli, do not produce cubits, do not have enzymes, oxidases and transports, can grow in Wei and anaerobic henna, the most suitable growth temperature is 37±rc, belonging to facultative heterogeneity Sexual strain 'When Xie Shi does not' (4). _____ 1. When cultured in MRS medium, the cells are short rod-shaped, and the two ends are Lactobacillus TE-33 round, usually appearing, lamming or short-chain. Gram-positive bacilli, which do not produce stalks, do not have enzymes, oxidases and motility, can grow in both aerobic and anaerobic environments, and the optimum growth temperature is 37±Γ〇, which is a facultative heterogeneous acid. The yeast strain does not produce gas during glucose metabolism. ---------________ Example 2: Effect of anti-allergic lactic acid bacteria on promoting the secretion of interferon-gamma-type TM immunity (by peripheral blood mononuclear cells) In vitro efficacy verification platform). To examine the effect of two strains of anti-allergic lactic acid bacteria strain Lactobacillus gl_104 strain bcrc 910404 and Lactobacillus sp. te-33 strain BCRC 910441 on Thl-type immunity. Peripherai blood mononuclear ceU, PBMC) and the aforementioned anti-allergic lactic acid bacteria were separately cultured to determine the amount of interferon γ secreted to verify the strain with anti-allergic ability. The following experimental steps were used: 1. Take appropriate human blood volume about 200 mL whole blood each time 7 2· Take an equal ratio of picdl-paque and blood at 300 g for 30-40 minutes at i8-2°°C. 3. Take the white blood cell layer of human peripheral blood and wash the cells for 2_3 times with buffer solution. The cells were suspended in a suitable medium (for example, RPMI-1640) 4. The cells were co-cultured with the lactic acid bacteria strain which had been activated for 3 days at a ratio of 1:1 for 48 hours. 5. The supernatant of the cell culture was collected and immunized with the enzyme. Analytical method (ELISA) to detect the content of interferon gamma (IFN-gamma) in the supernatant. The statistical analysis of the data is shown in Table 3 and Figure 1, expressed as Mean ± SD. Figure 1 shows the difference Co-cultivation of 1 〇 6 to 1 〇 8 cfo Lactobacillus GL-104 strain BCRC910404 and Lactobacillus reuteri TE-33 strain BCRC 910441 and 1〇5 to 1〇7 human peripheral blood mononuclear cells (PBMC) 48 hours, the cell supernatant was collected and detected by enzyme immunoassay The content of interferon gamma (IFN-gamma) in the supernatant was measured. Among them, the anti-allergic function lactic acid bacteria cose/BCRC 17001) and the experimental background value (Cell only) were negative control group. The allergic lactic acid bacteria r/ja/wwosus GG BCRC 16000) and PHA (Phytohemagglutinin) were positive control groups, and the interferon gamma stimulated concentration was detected. The results showed that the experimental group significantly stimulated the peripheral blood mononuclear sphere (PBMC) secreting interferon gamma and the negative control group BCRC 17001) and was 2.3 times higher than the positive control group GG BCRC 16000). 4.7 times (PBMC). Table 3 shows that the anti-allergic lactic acid bacteria strain and the control group of the present invention are cultured with human peripheral blood mononuclear cells (PBMC), respectively, to stimulate the secretion of interferon γ (means ± SD): Table 3 The name of the strain interferon γ Secretion amount Cpg/mL) Positive control group {L. rhamnosus GG BCRC 16000) 1587±585 Lactobacillus GL-104BCRC 910404 3587 95 Lactobacillus TE-33BCRC 910441 7473±624 Negative control group (L cosez·BCRC 17001) 533 153 positive control group (PHA) 1573 ± 61 negative control group (Cell only) 97 ± 27 Example 3: anti-allergic lactic acid bacteria to promote the secretion of interleukin 12p40 (EL-12p40) regulation of Thl-type immunity ( The dendritic cell is used as an in vitro efficacy verification platform). The effect of the anti-allergic lactic acid bacteria strain Lactobacillus sp. GL-104 strain BCRC 910404 of the present invention on the immunity of Th1 type is measured, and the dendritic cell is co-cultured with the anti-allergic lactic acid bacteria to determine the cell-to-cell relationship. The secretion amount of leucine 12p4 〇 (IL-12p40) was used to verify the strain having antiallergic ability. Use the following experimental procedure: 1. Draw an appropriate human blood volume of approximately 200 mL each time. 2. Take an equal ratio of Ficoll-paque and blood at 400g for 30-40 minutes at 18-20 °C. 3. Take the human peripheral blood mononuclear sphere (PBMC) layer, wash the cells 2-3 times with buffer solution, and suspend the cells in a suitable medium (such as RPMI-1640). 4. Human peripheral blood mononuclear sphere (PBMC) cells were purified from CD14+ mononuclear cells of the cells by CD14+ microbeads (MiniMACS system). 5. The cells were differentiated into dendritic cells by cytokines (IL-4) and growth hormone (GM_CSF), and the differentiated dendritic cells were collected at a culture time of 6-7 days. 6. The anti-allergic lactic acid bacteria strain was activated 3 days before the co-cultivation, and then the lactic acid bacteria strain was heat-killed at 100 ° C for 30 minutes. 7. The dendritic cells were co-cultured with the heat-killed lactic acid strain at a ratio of 1:10 for 48 hours. 8. Collect the supernatant from the cell culture. The content of intercellular white 12p40 (IL-12p40) in the supernatant was determined by enzyme immunoassay (EUSA).

The statistical analysis of the data is shown in Table 4 and Figure 2, expressed as Mean ± SD. Figure 2 shows the cell supernatants collected by heat-killing 1〇6 to 1〇8 Lactobacillus GL_1〇4 strain bcrc 910404 and 1〇5 to 1〇7 human dendritic cells, respectively, for 48 hours. The content of intercellular white 12p40 (IL-12p40) in the supernatant was detected by enzyme immunoassay. Among them, the anti-allergic function lactic acid bacteria 17001) and the experimental background value (Cell only) were negative control groups, and most of the literatures were published to prove that they have anti-allergic lactic acid bacteria (laCic^cz7/(10) GG BCRC 16000) and LPS (Lip〇p). 〇lySaccharide) is a positive control group that detects the concentration of interleukin 12P40 (IL-12p40) stimulated. The results showed that the experimental group significantly stimulated the stimulation of human dendritic cells to secrete intercellular white pigment 12p40 (IL-12P40) and the negative control group c(10)i BCRC 17001) and the stimulation amount of the positive control group mnosus GG BCRC 16000. 2 times higher. Table 4 shows the secretion of interleukolin 12p40 (IL-12p40) stimulated by heat-killing anti-allergic lactic acid bacteria strains and control groups and dendritic cells, respectively: Table 4: Strain name intercellular melanin Secretion amount of 12p40 (pg/mL) Positive control group {L. rhamnosus GG BCRC 16000) 6905±611 Lactobacillus GL-104 BCRC 910404 14425±1741 Negative control group (L. casei BCRC17001) 51±2 Positive control group ( LPS) 22103±780 Negative Control Group (Cell only) 20±147 1355272 Example 4: Anti-allergic lactic acid bacteria resistant to gastric acid bile salt test. The anti-allergic lactic acid strain of the present invention, the Lactobacillus sp. GL_1〇4 strain bcrc 91, has a function of the anti-allergic function by the stomach salt test, and the test procedure is as follows: 1. The anti-allergic lactic acid bacteria of the present invention are used. Activated for 3 days. 2. Take 1 mL of the bacterial solution and calculate the original number of bacteria. The remaining lactic acid bacteria are washed with deionized water for 2-3 times.

3. Add the medium containing hydrochloric acid to the mash, and mix the anti-allergic lactic acid bacteria of the present invention with the medium of the yang, and then place it in the “well incubator. 4. = hour to take out the broth of 丨mL and wash it with deionized water. 3 reading, calculate the number of viable cells 'to 3 hours of culture time. 5. After the remaining bacterial liquid is centrifuged, the sediments are re-dissolved in a medium containing 5% (w/v) bovine bile (4) butterfly, & (4). After mixing, the cells were cultured at 37 ° C. 6. After removing the bacterial solution of 丨 mL every hour for 2 to 3 times with deionized water, the number of viable cells was counted until 4 hours of culture time.

The growth rate of lactic acid patic acid and bile salts was calculated by centrifugation at 500 g for 10 minutes, and 7. The growth rate of lactic acid bacteria was recorded to compare whether the growth of the strain was inhibited in the presence of gastric acid and bile salts in the sample. The results and analysis of the ability to resist gastric acid are shown in Table 5 and Figure 3. The results shown in Figure 3 are not 'the anti-allergic lactic acid bacteria of the present invention. After the medium is activated, the strain is treated with an acidic buffer solution and a bile salt. g GL_1〇4 _BCRC 91_4 The number of bacteria is not impaired by the influence of gastric acid and bile salts. (4) The anti-worker of the present invention is tested by the strict environment of the human digestive system. Table 5 shows the gastric acid tolerance (L〇gmeanS±L〇g SD) of hydrochloric acid having a pH of 2.5 and the anti-allergic lactic acid bacteria of the present invention: 11 1355272 Table 5 Original bacteria number of the strain name (Log cfWmL) pH 2.5- Lhr (Log cfu/mL) pH2.5-2hr (Log cfu/mL) pH2.5-3hr (Log cfu/mL) Lactobacillus BCRC 910404 9.33±〇.〇12 9.15±0.15 8.92±0.28 8.49±0.14 The results and analysis of the capacity of bile salts are shown in Table 6 and Figure 3. Table 6 shows the ability to test bile salt with 1.5% bile mixed with the anti-allergic lactic acid bacteria of the present invention (L〇g means ± Log SD): _ Table 6 Original name of strain name (Log cfu/mL) 1.5%bile -lhr (Log cfu/mL) 1.5%bile -2hr (Log cfu/mL) 1.5%bile -3hr (Log cfu/mL) 1.5%bile -4hr (Log cfu/mL) Lactobacillus BCRC 910404 9·33±0·012 8.22±0.39 8.03±0.026 8.11±0.091 7.96±0.15 Example 5: Anti-allergic lactic acid bacteria on human intestinal epithelial cells (Caco-2) Adsorption capacity test. The ability of the anti-allergic lactic acid bacteria strain of the present invention to adsorb human intestinal epithelial cells (Caco-2) was analyzed in vitro using a differentiated cell strain. The human intestinal epithelial cell (Caco-2) monolayer cell strain was first grown on a cover glass to a monolayer, and then placed in a multi-well cell culture dish. Then, the ratio of the cells: lactic acid bacteria was 1:200, and the cells were co-cultured for 1-3 hours. After washing with a buffer solution and fixing the cells with sterol and the remaining number of adhering bacteria, Gram staining was performed to determine the number of attached bacteria. Referring to the analysis method of Jacobsen et al. (1999), 20 fields of view were counted under a 1000-fold microscope, and when the average number of bacteria per field of view was less than 40, it was judged as nonadhesive; when the average number of bacteria per field of view When it is between 41 and 1 ,, it is judged to be attached; when the average number of bacteria per field of view is more than 1 ,, the statistical analysis of the data which is judged to be strongly adhesive is expressed by Mean ± SD. On average, the calculated values of 45 fields of view 12 1355272' are compiled in Tables 7 and 4. Fig. 4 shows that the road lactic acid stick g GL_1〇4 strain BCRC 910404 was judged to be "strongly attached". Table 8 shows the adsorption capacity of the resistant lactic acid bacteria against human intestinal epithelial cells (Caco-2) cell line. Table 7 strain name Means±SD Lactobacillus BCRC 910404 204±58 Because lactic acid g should exert anti-allergic effects in addition to strains with specific functions, it is necessary to confirm that the strain can pass the environment of human stomach acid bile salts, The lactic acid bacteria strain which has good adsorption ability to small intestinal mucosal epithelial cells, and because of such characteristics, the anti-allergic lactic acid bacteria of the present invention can provide medical treatment for treating or soothing allergy symptoms. The anti-allergic lactic acid bacteria described in the present invention can simultaneously enhance the allergic reaction of the Th1 pathway to regulate muddy excess. The goal of this development is to continue to achieve this fresh desire or at least provide the public with a new choice of alcohol in the allergy treatment scene or anti-spoken ammonia. The present invention finds (4) the anti-allergic lactic acid bacteria which are beneficial to the human body and have a healthy effect. New choice for allergy treatment. The embodiments described above are only for explaining the technical idea and characteristics of the present invention, and the purpose thereof is to enable the person skilled in the art to understand (10) of the present invention and implement it according to the present invention. Variations or modifications other than those of the spirit of the present disclosure are still to be included in the scope of the present invention. [Simple description of the diagram] Figure 1 shows that when there are 1〇6 to 108 cfU pathways, Lactobacillus GL carries strain BCRC 910404, Lactobacillus kawaii 33 strain BCRC 91〇441 and ... to π human peripheral blood Mononuclear cells (PBMC) were co-cultured for 48 hours, and the supernatant of the cells was collected, and the content of the pre-prime γ (leg·ga_) in the supernatant was measured by enzyme immunoassay. Z^c herna (10) BCRCn 〇〇 1) and experimental background values (four) (four) for the face group 'to publish most of the literature to prove that it has anti-allergic effect of milk 13

Acid bacteria (Zacii r/wwmmy GG BCRC 16000) and PHA were positive control groups, and the interferon gamma stimulated concentration was detected. The results showed that the experimental group significantly stimulated the secretion of interferon-gamma from the peripheral blood early nucleus (PBMC) and the negative control group (heart BCRC17001) was significantly different from the positive control group (Ζαί;/οΖ>α£^7/ The stimulus amount of «ί GG BCRC 16000 is 2.2 times and 4.7 times higher. Figure 2 shows that cell supernatants were collected by co-cultivation of Lactobacillus GL-104 strain BCRC 910404 with 105 to 1-7 dendritic cells by heat-killing 1〇6 to i〇8cfb, respectively. In the solution, the enzyme-containing immunoassay was used to detect the inclusion of interleukin ι2ρ4〇 in the upper and/or monthly solution. Among them, there were no anti-allergic lactic acid bacteria (2/〇^〇6^2£^7/milk eiwez·BCRC17001) and experimental background values (Cell only) as the negative control group, and most of the literatures were published to prove that they have anti-allergic lactic acid bacteria. (Ι^ίο6<3ί^7/Μ5 r/wmwfWMj GG BCRC 16000彡 and LPS were positive control groups, and the intercellular leukotriene i2p40 (IL-12p40) was stimulated. The results showed that the experimental group could significantly stimulate the human tree. The cytokine secretion of intercellular leukotriene 12p4〇 (IL-12p40) was significantly different from the negative control group cosez* BCRC 17001) and was twice as high as that of the positive control group (Zflcic^c^usr/zoTTmamsGGBCRClGOOO). Figure 3 shows that the total number of bacteria in the Lactobacillus glabrata GL-104 strain BCRC910404 after the activation of the medium was treated with the simulated gastric acid solution and the bile salt solution for different times, and the number of bacteria of the Lactobacillus GL-104 strain BCRC 910404 was not affected by gastric acid and The effect of bile salts is drastically reduced. f. The anti-allergic lactic acid bacteria strain of the present invention can pass the test of the strict environment of the human digestive system. Figure 4 shows that according to the analysis method of jac〇bsen et al. (1999), when the average number of bacteria per field of view is less than 40, it is judged as nonadhesive; when the average number of bacteria per field is between 41 and When it was 1 ,, it was judged to be attached (acjhesive); when the average number of bacteria per field of view was more than 100, it was judged to be strongly adhesive. Lactobacillus sp. GL-104 strain BCRC 910404 was judged to be "strongly attached". 1355272 [Description of main component symbols] None

15

Claims (1)

1355272 VII. Patent Application Range: j Announcement 1. A food composition comprising: • a lactic acid bacteria strain that stimulates immune cells to secrete anti-allergic-related cytokines selected from the group consisting of biological cultures of any one or more of the following combinations: Lactobacillus m^m_) GL-l〇4 strain, accession number BCRC 910404 and Lactobacillus sp. (10) 7/usrewter〇TE-33 strain, accession number BCRC910441, all of which were deposited in Taiwan Hsinchu Food Industry Development Research Institute (FXRD) ); and a physiologically acceptable excipient or diluent. 2. The food composition according to claim 1, wherein the lactic acid bacteria strain is Lactobacillus sp. GL_104 strain, accession number BCRC 910404. 3. The food composition according to claim 1, wherein the lactic acid bacteria strain is Lactobacillus strain L-33 strain, the accession number BCRC91〇44, 4. The food composition according to claim ,, wherein the excipient Or thinner is a food. 5. The food composition of claim 4, wherein the food comprises fermented milk, yogurt, milk, milk powder, tea, coffee or a combination thereof. 6. The food composition of claim 1, wherein the lactic acid bacteria strain is an active or inactivated strain. Lu 7· a pharmaceutical composition comprising: a lactic acid bacteria strain stimulating immune cells to secrete an anti-allergic-related cytokine, the strain being selected from the biological culture of any one or more of the following combinations: Lactobacillus sp. m^n_) GL-l 〇4 strain, accession number BCRC 910404 and Lactobacillus strain, storage number BCRC91〇441, all of the above strains, deposited in Taiwan Hsinchu Food Industry Development Research Institute (FIRDI); and. Pharmaceutically acceptable excipients or thinners . The pharmaceutical composition according to claim 7, wherein the lactic acid bacteria strain is Lactobacillus sp. GL-104 strain, and the accession number is BCRC91〇4〇4. 9. The pharmaceutical composition according to claim 7, wherein the lactic acid bacteria strain is Lactobacillus sp. 16 1355272 TE-33 strain, accession number BCRC910441. The pharmaceutical composition according to claim 7, wherein the lactic acid bacteria strain is an active or inactivated strain. 17